Franklin Genomic Advancements ETF (HELX) Options Open Interest

Monitoring HELX open interest helps you see where real money is positioned on Franklin Genomic Advancements ETF's options and which strikes are attracting the most commitment from traders. Franklin Genomic Advancements ETF's open interest reflects the total number of outstanding contracts that have not been closed or exercised, making it a powerful gauge of liquidity, conviction, and potential support and resistance zones. Use our scanner to monitor HELX options open interest in real time and find the strikes that matter.

Open interest is distinct from volume: volume counts how many contracts are traded in a session, while open interest counts how many remain open at the end of the day. Rising HELX options open interest alongside rising volume suggests new positions are being built, while falling open interest signals positions are being closed. Heavy open interest at specific strikes often acts as a magnet near expiration and can hint at where dealers and large traders expect Franklin Genomic Advancements ETF to settle.

The fund seeks capital appreciation by investing in equity securities inside and outside of the United States, including developing or emerging markets. The fund invests in companies that are relevant to its investment theme of genomic advancements that the investment manager believes are substantially focused on/or are expected to substantially benefit from extending and enhancing the quality of human and other life (e.g., animals) by incorporating technological and scientific developments, improvements and advancements in the field of genomics into their business.

Pin risk into expiration, dealer positioning, liquidity checks for large orders — all of it starts with knowing where HELX open interest is concentrated. Our scanner maps Franklin Genomic Advancements ETF's open interest across every strike and expiry, flags unusual buildups, and lets you drill into the contracts that institutional money is actually holding. Trade Franklin Genomic Advancements ETF's options open interest as the signal it is, not as an afterthought.